East® Clinical Trial Design Software Reviews

"We use East® regularly here at AstraZeneca to explore and produce the best design possible for many types of trials."

"With East®, we can more effectively evaluate various design options and when appropriate implement group-sequential trial designs, including adaptive sample size re-estimation."

"Cytel’s customized version of East® for AZ now integrates with our clinical data system to better facilitate the data analysis process, avoiding manual data handling. The cooperation between AstraZeneca and Cytel has been very good."

"By increasing our use of Cytel's East, we now more effectively evaluate our options and implement the optimal trial design, including adaptive sample size re-estimation studies. East also helps to compare trial strategies with our clinical teams and management."

"The latest version, East® 5, is a unique tool for collaborative planning, helping our statisticians and clinicians to better focus precious development resources on the most promising studies."

"I recently needed to insert an interim look 20% of the way into a trial, because of unexpectedly slow accrual. Using East, it took me just one day to make the adjustment, and I know everything is accurate. Without East, I don't know what I would have done. It probably would have taken a whole week of work. East is absolutely instrumental to my work."

"East’s elegant user interface makes sequential designs very straightforward. We have East on every statistician’s desktop. The benefits are clear – we recently used East to insert interim looks into a study on colon cancer, and by crossing a null boundary early we decreased time to publication by two years."

"I started using East as a statistical review tool during my tenure at the FDA/CDER, and have continued to use it as an industry statistician to design and analyze flexible and group sequential studies because of its user friendliness and industry wide acceptance. Because East is used widely by both industry and regulatory statisticians, I think it is now much easier for industry statisticians to communicate with regulatory statisticians regarding study designs and analysis results based on the software.”

Review of East

Review of East